Table 1.
Demographic and clinical patients’ characteristics at baseline.
| Patients (N = 453) | |
|---|---|
| Age (years) | |
| median (q1–q3) | 77 (71–82) |
| 75 years, n (%) | 265 (58.5) |
| PSA (ng/ml), median (IQR) | 15.0 (4.7–41.5) |
| Extent of disease, n (%) | |
| Bone only | 190 (41.9) |
| Bone + lymph nodes only | 103 (22.7) |
| Lymph nodes only | 99 (21.9) |
| Visceral | 38 (8.4) |
| Othera | 23 (5.1) |
| Bone metastases, n (%) | |
| <10 | 225 (78.1) |
| ⩾10 | 63 (21.9) |
| No bone metastases | 133 |
| Missing | 32 |
| Time from first prostate cancer diagnosis to abiraterone (months), median (IQR) | 62.1 (27.0–111.9) |
| Time from ADT start to abiraterone (months), median (IQR)b | 34.7 (13.7–72.4) |
| ECOG-PS, n (%) | |
| 0 | 251 (56.7) |
| 1 | 169 (38.1) |
| ⩾2 | 23 (5.2) |
| Missing | 10 |
| No. of comorbidities, n (%) | |
| 0 | 142 (31.3) |
| 1 | 138 (30.5) |
| ⩾2 | 173 (38.2) |
| Type of comorbidityc, n (%) | |
| Cardiovascular disordersd | 260 (57.4) |
| Metabolic disorderse | 105 (23.2) |
| CSN disorders | 26 (5.7) |
| Renal disorders | 16 (3.5) |
| Hepatic disorders | 9 (2) |
| Hormonal disorders | 3 (0.7) |
| Other disorders | 91 (20.1) |
CSN, central nervous system; ECOG-PS, Eastern Cooperative Oncology Group performance status
IQR, interquartile range; PSA, prostate-specific antigen.
a
Including prostatic bed (n = 12) and prostate (n = 4).
b
One missing value.
c
A patient could have more than one relevant medical condition/disease.
d
Hypertension: 48.6%; history of myocardial infarction: 5.5%; arrhythmia: 4.4%; cardiomyopathy: 3.5%; angina pectoris: 0.7%; atherosclerosis: 0.4%; other: 8.8%.
e
Hypercholesterolemia 11.5%; diabetes 10.8%; hyperglycemia: 0.7%; obesity: 0.7%; other: 5.1%.